ABCL EPS
Net income divided by diluted shares outstanding — the per-share profit earned each quarter.
EPS
Latest: −$0.18 (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | −$0.14 |
| 2023Q2 | −$0.11 |
| 2023Q3 | −$0.10 |
| 2023Q4 | −$0.16 |
| 2024Q1 | −$0.14 |
| 2024Q2 | −$0.13 |
| 2024Q3 | −$0.17 |
| 2024Q4 | −$0.12 |
| 2025Q1 | −$0.15 |
| 2025Q2 | −$0.12 |
| 2025Q3 | −$0.19 |
| 2025Q4 | −$0.03 |
| 2026Q1 | −$0.14 |
| 2026Q2 | −$0.18 |
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 8
Revenue
Free Cash Flow
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Rule of 40
Healthcare Comparison
1 / 3
Latest EPS: −$0.18 (2026Q2); −50.0% YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, EPS ranged from −$0.19 in 2025Q3 to −$0.03 in 2025Q4.